Shopping Cart
- Remove All
- Your shopping cart is currently empty
GSK3532795 is a potent, orally active, second-generation HIV-1 maturation inhibitor (EC50s: 10.2, 1.9, 2.7, and 13 nM for HIV-1 WT(human serum), HIV-1 WT, HIV-1 V370A, and HIV-1 ΔV370).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,970 | 8-10 weeks | |
50 mg | $2,580 | 8-10 weeks | |
100 mg | $3,400 | 8-10 weeks |
Description | GSK3532795 is a potent, orally active, second-generation HIV-1 maturation inhibitor (EC50s: 10.2, 1.9, 2.7, and 13 nM for HIV-1 WT(human serum), HIV-1 WT, HIV-1 V370A, and HIV-1 ΔV370). |
Targets&IC50 | HIV-1 (V370): 13 nM , HIV-1 (V370A): 2.7 nM , HIV-1 (WT): 10.2 nM , HIV-1 (WT):(EC50)1.9 nM |
In vitro | GSK3532795 demonstrates binding affinities, expressed as equilibrium dissociation constants (Kds), of 3.2 ± 0.6 nM for HIV wild-type (WT), 4.3 ± 2.0 nM for the HIV V362I variant, 6.5 ± 2.2 nM for the HIV V370A variant, and 33.6 ± 5.9 nM for the HIV ΔV370 variant, indicating its effectiveness in targeting different forms of HIV. |
Alias | BMS-955176 |
Molecular Weight | 691.02 |
Formula | C42H62N2O4S |
Cas No. | 1392312-45-6 |
Relative Density. | 1.19 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.